The study of Heitkötter et al. highlights strong positivity for PSMA especially in malignant tumors (6.51%), a value which was exceeded in our study (31.5%), owing to both malignant soft tissue tumors (29.1%) and malignant bone tumors (33.4%) (Table 1). Here, FOLH1 is linked to bone cancer.